Results 241 to 250 of about 509,395 (261)
Some of the next articles are maybe not open access.
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
New England Journal of Medicine, 2019Jean Kim, Andrew Potter, Robert Temple
exaly
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
New England Journal of Medicine, 2017Richard Pazdur +2 more
exaly
Failing the Public Health — Rofecoxib, Merck, and the FDA
New England Journal of Medicine, 2004Eric Topol
exaly
The FDA Breakthrough-Drug Designation — Four Years of Experience
New England Journal of Medicine, 2018Jonathan J Darrow, Aaron Seth Kesselheim
exaly
FDA Oversight of Postmarketing Studies
New England Journal of Medicine, 2017Mwango Kashoki, Peter Stein
exaly
The FDA Sentinel Initiative — An Evolving National Resource
New England Journal of Medicine, 2018Robert Ball +2 more
exaly

